Low Dose Cyclophospahamide is a Feasable Mobilization Regimen in the Covid-19 Era: A Single Center Study from Türkiye.

The aim of this study was to investigate the effectiveness and safety of low dose cyclophosphamide (Cy) as a mobilization regimen in multiple myeloma and lymphoma patients during covid-19. This is a single-center retrospective study conducted at Stem Cell Transplantation Unit of University of Health Sciences Adana City Training and Research Hospital, between September 2020 and August 2022. Fourty-one patients who underwent stem cell mobilization with low dose cyclophosphamide plus granulocyte colony stimulating factor (G-CSF) were included. Cyclophosphamide was administered with a dosage of 2000 mg/m2/day for one day and G-CSF was started at a dosage of 10 μg/kg/day 2 or 5 days after the Cy application and was continued until obtaining adequate product or mobilization failure. The median age of the patients at the time of mobilization was 57 years (range, 21-68). Eighteen (43.9%) patients were female and 23 (56.1%) were male. An adequate number of CD34+ cells were collected in 38 (92.7%) patients with a product yield of ≥ 2 × 106/kg CD34 + cells while the rate of mobilization failure was 7.3% (3 of 41). In conclusion, low dose Cy with G-CSF seems to be an effective mobilization regimen prior to ASCT with a reasonable toxicity in the era of Covid-19 disease.